Folfox+Irinotecan+Chemort In Esophageal Cancer
Last updated on July 2021Recruitment
- Recruitment Status
- Not yet recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Esophagogastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: N/AIntervention Model: Single Group AssignmentMasking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. This research study involves the following standard of care interventions: FOLFOX (leucovorin calcium, 5-Fluorouracil, and oxaliplatin) Carboplatin Paclitaxel Radiation the...
The research study procedures include screening for eligibility and study treatment including evaluations and follow up visits. This research study involves the following standard of care interventions: FOLFOX (leucovorin calcium, 5-Fluorouracil, and oxaliplatin) Carboplatin Paclitaxel Radiation therapy This research study involves the following study intervention: - Liposomal irinotecan It is expected that about 40 people will take part in this research study. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied. The U.S. Food and Drug Administration (FDA) has not approved liposomal irinotecan for your specific disease but it has been approved for other uses. The FDA has approved FOLFOX, carboplatin, and paclitaxel as treatment options for this disease.
Tracking Information
- NCT #
- NCT04656041
- Collaborators
- Ipsen
- Investigators
- Principal Investigator: Theodore S Hong, MD Massachusetts General Hospital
Get Well Soon